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Background: Cementum formation is deemed to be instru-
mental for the successful regeneration of periodontal tissues,
and thus events and modifiers of cementum formation and
mineralization need to be determined. This study aimed to de-
termine whether the bisphosphonate 1-hydroxyethylidene-1,
1-bisphosphonate (HEBP) altered the behavior of immortal-
ized cementoblasts (osteocalcin-cementoblasts [OCCM]).
Methods: OCCM from transgenic mice were exposed to
HEBP at concentrations ranging from 0.01 to 10.0 mM. The
assays performed included the count of cell number for prolif-
eration, Northern blot analysis for gene expression (up to 10
days for core binding factor alpha-1 [Cbfa1], bone sialoprotein
[BSP], osteocalcin [OCN], and osteopontin [OPN], markers
for cementoblast/osteoblast maturation/mineralization), von
Kossa stain and alizarin red S stain for mineralization, and en-
zyme assay (p-nitrophenol phosphate cleavage) for alkaline
phosphatase (ALP) activity.
Results: Mineral nodule formationwas inhibited at the high-
er doses of HEBP (1.0 and 10.0mM) only. At early stages (1, 3,
and 6 days), gene expression assays revealed only subtle
changes in treated cells versus untreated cells, but by day
10, groups treated with lower doses (0.01 and 0.1 mM) were
markedly different at the gene expression level. OCN was sig-
nificantly downregulated (70%) at the lowest dose, with less
pronounced effects at higher doses. In concurrence, the
master switch gene for osteoblasts, Cbfa1, was also down-
regulated at the lower doses. Inversely, OPN mRNA was
enhanced at the lower doses. ALP activity was not altered by
HEBP.
Conclusion: Bisphosphonate alters cementoblast function
in vitro through the regulation of gene expression and mineral
formation. J Periodontol 2005;76:1890-1900.
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A
major challenge of regenerative
periodontal procedures is de-
signing therapies that reliably
restore periodontal tissues including soft
tissue attachment, cementum, and alve-
olar bone lost to disease. In vitro inves-
tigations provide an opportunity to focus
on the defining factors and mediators of
individual components of the periodon-
tium, such as cementoblasts.
Examples of recognized mediators of
bone metabolism include bisphospho-
nates (BPs). BPs are primarily known
as potent inhibitors of bone resorption.1
They are commonly prescribed for the
prevention and treatment of bone meta-
bolic diseases, including osteoporosis,
Paget’s disease, and tumor-associated
osteolysis.2 The antiresorptive property
of BPs might also be beneficial in reduc-
ing and preventing bone resorption asso-
ciated with periodontitis.3 Initially, the
interest in BPs was related to their inhibi-
tion of mineralization, attributed to phys-
icochemical phenomena.4 At that time,
thediscovery of their antiresorptive prop-
erties offered new therapeutic perspec-
tives. Most recently, anabolic actions of
BPs on bone-forming cells have been re-
ported in vivo and in vitro.5-7
Structurally, BPs are analogs of pyro-
phosphate (PPi), which is used as an
ingredient in toothpaste to control
calculus formation. As derivatives of in-
organic phosphate, BP differs from PPi
by a carbon atom replacing the oxygen
atom and creating P-C-P bonds. Their
specific properties include the ability to
resist enzymatic hydrolysis and a strong
affinity tometal ions and calcium, forming
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both soluble and insoluble complexes. The bone-
seeking feature of BPs may be responsible for impair-
ing mineralization. Once BP is deposited on the bone
surface, it is internalized through pinocytosis8 and ex-
erts intracellular effects rather than extracellular ef-
fects in osteoclasts.9 The potency of the molecule
is attributed to its lateral group, and the mechanism
of action depends on the absence or presence of a
nitrogen. The nitrogen-containing bisphosphonates
(N-BP) include alendronate, pamidronate, and others.
Examples for non-N-BPs are clodronate and etidro-
nate. N-BPs inhibit farnesyl diphosphate synthase,
an enzyme of the mevalonate pathway. As a result,
the formation of isoprenoid geranylgeranylated pyro-
phosphates and guanosine 59-triphosphate (GTP)
binding proteins is prevented,10 which is necessary
for downstreamevents in signaling of changes in cellu-
larmorphological characteristics, integrins,membrane
ruffling, trafficking, and apoptosis.11 In contrast, the
non-N-BPs are metabolized to cytotoxic adenosine
59-triphosphate (ATP) analogs and are accumulated
intracellularly leading to apoptosis.12 These two dis-
tinctively different mechanisms indicate two pharma-
cological classes of BP.13
Findings from a clinical trial for the treatment of os-
teoporosis raised the question of the possible anabolic
action of BPs in promoting bone formation,14 which
was further supported by studies reporting a direct ef-
fect of BPs on osteoblasts in vitro and in vivo.5-7 How-
ever, opposing findings on osteoblast behavior in vitro
ranging from stimulatory to inhibitory have been re-
ported,most likely related to the cell type, stage of cell
development, type of BP, concentration, and duration
of treatment. Components of the extracellular matrix
(ECM) are markers of cell activity characteristic for
mineralizing tissues. Non-collagenous proteins have
been implicated in the selective migration and adhe-
sion of cells at the root surface to maintain a homeo-
stasis between breakdown and mineral formation.
Interestingly, the proteins that appear to be key regu-
lators ofmineralization, osteopontin (OPN), osteocal-
cin (OCN), and bone sialoprotein (BSP) are reported
to be major non-collagenous components of cemen-
tum.15,16 Other identified non-collagenous proteins
in cementum are osteonectin,17 fibronectin,18 g-car-
boxyglutamic acid,19 and alkaline phosphatase
(ALP).20Additionally, an upregulation of ALP is asso-
ciated with matrix maturation, an initial event in oste-
oblast differentiation, and this is enhanced when BPs
are delivered in low dosages (e.g., 1-hydroxyethyli-
dene-1,1-bisphosphonate [HEBP; generic name:
etidronate]).5,6,21
Currently, the precise mechanism by which BPs
control cells involved in the formation of mineralizing
tissues is unknown. Based on the evidence that BPs
affect osteoblasts, it was of interest to characterize
the cementoblastic response to HEBP by cell prolifer-
ation, cell viability, cell morphology, formation of
mineral nodules, and gene/protein levels for mineral
associated genes. The cementoblasts used here are
considered a mature cell line.
MATERIALS AND METHODS
Cementoblast Cell Culture
Cementoblasts were isolated from a transgenic
mouse (osteocalcin T-antigen [OC-TAg]), containing
a transgene composed of the SV 40 large T-antigen
under the control of the osteocalcin promoter. There-
fore, only cells that expressed osteocalcin (OCN) ex-
pressed TAg concurrently and were immortalized in
vitro. The cell isolation was done on mice 41 days
from vaginal plug date, since at this time cemento-
blasts are known to express high mRNA levels for
the mineralization markers BSP and OCN.22 The ce-
mentoblasts were harvested from the root surfaces
avoiding contamination with osteoblasts by diligent
dissection of the periodontal ligament (PDL) fibers.23
The teeth were digested using collagenase/trypsin,
and then the cells, designated OCCM (osteocalcin-
cementoblasts) were placed in culture. To confirm that
the cells’ phenotype was maintained during culturing,
subclones from single cells were analyzed for the ex-
pression of cementoblast markers. The selected sub-
clone, 30, expressed high mRNA levels for BSP and
OCN. This phenotype was maintained when the cells
were cultured. The isolation of the cementoblasts from
developed root surfaces and the presence of the ce-
mentoblast markers, OCN and BSP, indicate a mature
cell stage. Contamination with PDL cells was of minor
concern because PDL cells do not express OCN and
consequently do not survive repeated passage.22
The permission to obtain murine cementoblasts was
granted from the University Committee on Use and
CareofAnimals (UCUCA)of theUniversityofMichigan
to ensure the humane treatment and judicious use of
animals.
OCCMs were seeded in six-well plates at a density
of 1000 cells/ml in triplicate. Cells weremaintained in
Dulbecco’s modified Eagle’s medium (DMEM)§ sup-
plemented with 10% fetal bovine serum (FBS), 100
units/ml penicillin, and 100 mg/ml streptomycini until
they reached confluency, designated as day 0. De-
pending on the assay, cells were cultured in mineral-
ization media defined as 2% or 5% FBS, 50 mg/ml
ascorbic acid, and 5 mM b-glycerophosphate.¶ The
ascorbic acid served to facilitate type I collagen
(Col I) synthesis24 and the b-glycerophosphate
served to induce mineral formation.25 The test agent,
§ Invitrogen, Carlsbad, CA.
i Invitrogen.
¶ Sigma, St. Louis, MO.
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HEBP,# was supplemented in concentrations of 0.01,
0.1, 1.0, and 10.0 mM. Media were changed every
other day. All experiments were repeated on three
separate occasions.
Proliferation Assay
To determine the concentration range and to rule out
the toxicity of HEBP, proliferation assays were per-
formed at logarithmic concentrations ranging from
0.01 to 10.0 mM. These concentrations were selected
based on in vitro studies with HEBP in osteoblasts.5
To determine the cell number, cells were trypsinized
and cell counts taken on days 0, 1, 6, and 10 using
a Coulter counter.
Cell Viability by Trypan Blue Assay
A trypan blue assay was used to discriminate viable
from non-viable cells. This was performed in parallel
with the proliferation assays and also with the dose-
response (HEBP doses 0 to 10 mM) and time-course
experiments (days1, 6, and10). Trypsinized cellswere
added to 0.4% trypan blue stain.** The percentage of
non-viable cells was identified by the uptake of dye.
Cell Morphology
Cell morphology was observed under a light micro-
scope to confirm cell viability and monitor the cell
shape. Cell appearance was documented with ran-
domly selected photographs on days 0, 1, 6, and 10.
Mineralization Assays by von Kossa Staining
and Alizarin Red S
The ability to induce mineralization in vitro is one of
the hallmark characteristics of cells associated with
hard-tissue formation. Two types ofmineralization as-
says were performed: von Kossa staining26 for visual-
ization (i.e., qualitative stains for phosphate inmineral
nodules) and alizarin red S staining for the quantifica-
tion of calcium deposition.27 Cells were treated with
HEBP at concentrations of 0.01, 0.1, 1.0, and 10.0
mM, based on the proliferation results. On days 5
and 8 and at the end of incubation (day 10), cells were
fixed in methanol and stained with AgNO3 for the von
Kossa assay. For quantifying the calcium content of
the mineral nodule formation, identical wells were
stained with alizarin red S. For this assessment, cells
were fixedwith a 1:1mixture (volume/volume) of 37%
formaldehyde and ethanol for 5 minutes, washed
three times with distilled water, and stained for 10 mi-
nutes with a 2% solution of alizarin red S (pH adjusted
to 4.2) dissolved in water. Spectrophotometric quan-
tification at 525 nm was done after alizarin red S was
redissolved.
Gene Expression by Northern Blot Analysis
To analyze changes in the OCCM phenotype at the
mRNA level, Northern blots were performed. The
genes of interest associated with mineral-forming
cells used in this study were core binding factor
alpha-1 (Cbfa1), OCN, BSP, OPN, and Col I. Once
confluency was reached, the media were changed
to mineralization media with 5% FBS, and treatment
with HEBP was started. RNA was harvested on days
1, 3, 6, and 10 according to the procedure of Xie
and Rothblum.28 Total cellular RNA was isolated us-
ing a modified guanidine thiocyanate procedure††
and quantified by a spectrophotometer at 260 nm.
RNA was denatured and size fractionated in a 6%
formaldehyde, 1.2% agarose gel. The fractionated
RNA was then transferred onto a nylon membrane‡‡
and cross-linked by ultraviolet (UV) irradiation.§§
Blots were hybridized with random-primed 32-P radio-
labeled probes,ii at 68C, washed at high stringency,
and exposed to film¶¶ at -70C with intensifying
screens for 24 to 72 hours.
The following probes were used: Cbfa1 (a gift from
Dr. G. Karsenty, Department of Molecular and Human
Genetics, Baylor College of Medicine, Houston,
Texas),29 BSP (M-BSP consisting of 1 kb mouse
cDNA in PCR IIc; a gift from Drs. M. Young and L.
Fisher, National Institute of Dental and Craniofacial
Research/National Institutes of Health [NIDCR/NIH],
Bethesda, MD),30 OPN (MOP-3 consisting of 1 kb
mouse OPN cDNA in PCR II37; a gift from Drs. M.
Young and L. Fisher, NIDCR/NIH),31 OCN (400 base
pairs [bp] of mouse OCN in pSP65; a gift from Dr. J.
Wozney, Genetic Institute, Wyeth Ayerst Research,
Cambridge, Massachusetts),32 and type I collagen
(consisting of 1 kb bovine type I collagen in Blue-
script; a gift from Drs. M. Young and L. Fisher,
NIDCR/NIH). Hybridized blots were scanned and
quantitated. To compensate for differences in load-
ing, the density of specific RNAs were normalized to
18S rRNA and expressed as a ratio.
Alkaline Phosphatase Activity Assay
Alkaline phosphatase is an early marker of differenti-
ation in cells that promote mineral formation and is
involved in controlling phosphate metabolism. ALP
catalyzes the cleavage of a phosphate group from
a variety of compounds, and its activity is measured
by its ability to cleave phosphate from p-nitrophenyl-
phosphate (PNPP), a reaction that can be quantitated
spectrophotometrically.
Cells were plated at 1,000 cells/ml in triplicate.
Upon confluence, designated day 0, media were re-
moved, and cells were incubated in mineralization
media containing 5% FBS and supplemented with 50
mg/ml ascorbic acid and 5 mM b-glycerophosphate.
# Strem Chemicals, Newburyport, MA.
** Invitrogen.
†† Trizol reagent, Invitrogen.
‡‡ Duralon-UV membrane, Stratagene, La Jolla, CA.
§§ Stratalinker, Stratagene.
ii Rediprime, Amersham-Pharmacia Biotech, Arlington Heights, IL.
¶¶ X-OMAT or Biomax MS, Eastman Kodak, Rochester, NY.
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While experimental wells were treated up to 10 days
with mineralization media and HEBP at a concentra-
tion of 0.0, 0.01, 0.1, 1.0, and 10.0 mM, the control
well received 10% FBS, DMEM, and antibiotics but
without ascorbic acid or b-glycerophosphate. Media
and HEBP were changed every other day. On day 5
and at the end of incubation on day 10, alkaline phos-
phatase activity was determined. Cells were washed
with phosphate buffered saline (PBS), removed into
2 mM phenylmethlysulfonyl fluoride (PMSF), and
sonicated.Cell lysateswerecentrifuged for20minutes
at 1500 · g, and the supernatants were used for the
enzymeassaydescribedabove.Theexperimentswere
carried out three times.
Statistical Analysis
All experiments were carried out three times, on
separate occasions, with similar results. Results
were compared using the mean – SD. For statistical
analysis, one-way analysis of variance (ANOVA)
and Tukey-Kramer multiple comparison tests were
performed.##***
RESULTS
Table 1 summarizes the results discussed below. The
cementoblast response depended highly on the dose
of HEBP treatment: low doses (0.01 and 0.1 mM) ver-
sus high doses (1.0 and 10.0 mM). In brief, at the
higher doses, the cementoblast phenotypewas not al-
tered, but mineral formation was blocked. The abro-
gation of mineralization was most likely attributed to
physicochemical phenomena. In contrast, at the
lower doses, the most evident finding was a modula-
tion of gene expression. Cbfa1 andOCNmRNA levels
were downregulated, whereas OPN mRNA was in-
creased. Mineral formation was observed in controls,
and this effect was not altered by low doses of HEBP.
Similarly, HEBP did not induce alkaline phosphatase
activity in cementoblasts.
Effect of HEBP on OCCM Proliferation (Fig. 1)
Proliferation assays were analyzed using a Coulter
counter to determine the dose-dependent effects of
HEBP on OCCMs. As shown in Figure 1, similar pro-
liferation rateswere obtained forHEBP-treated cells at
all doses versus untreated cells throughout the entire
10-day experimental phase. Cells grew in logarithmic
phase up to day 6 and then reached a plateau phase
with confluence.
Effect of HEBP on Cell Viability (Fig. 2)
Reports of cell death induced by BPs prompted us to
determine cell viability, using trypan blue staining.
Approximately 8% to 14% cell death is noted at all
time points, independent of HEBP treatment. At day
Table 1.








Cbfa1 OCN Col I BSP OPN
Control + + + + + + + +
Low* – – – Y Y – – [
High† – – Y‡ – – – – –
* Low doses of HEBP: 0.01 and 0.1 mM.
† High doses of HEBP: 1.0 and 10.0 mM.
‡ Abolished.
+ = expressed; – = no change; Y = decreased; [ = increased.
Figure 1.
Effect of HEBP on proliferation. Cementoblasts were cultured in
media with 2% FBS and ascorbic acid with or without HEBP.
## Excel 9.0, Microsoft, Redmond, WA.
*** GraphPad InStat 3.0, GraphPad Software, San Diego, CA.
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6, the average of non-viable cells decreased to <4%.
An increase in cell death was noted from days 6 to
10, most likely related to overconfluency (see Fig.
1; plateau effect), and thus a certain percentage of
cells were unable to adhere and survive. HEBP-treated
cells at all doses exhibited the same pattern as treated
cells (Fig. 2).
Effect of HEBP on Cell Morphology (Fig. 3)
Changes in cell morphology are one indication
of changes in cell phenotype. Here, cell morphology
appeared to beminimally affected byHEBP treatment
at all four doses up to 10 days when compared to
the control (Fig. 3). A slightly more cuboidal versus
fibroblastic appearance was suggested at day 6 at
10 mM and at day 10, at the highest doses of HEBP,
at 1 and 10 mM.
Effect of HEBP on Mineralization (Fig. 4)
Mineralization was evaluated from days 5 to 10 to de-
terminewhether or not HEBPwould promote or inhibit
mineralization. As expected, neither untreated nor
BP-treated cells mineralized at day 5. In accordance
with previous data, OCCM formedmineral nodules af-
ter 8 days, as visualized by von Kossa staining and
quantified by alizarin red S staining (Fig. 4). At doses
of 0.01 and 0.1 mM, HEBP mineralization was un-
disturbed, while at high doses (1.0 and 10.0 mM),
mineralization was completely suppressed. A longer
exposure time to HEBP (10 days) did not lead to fur-
ther differences in mineralization versus those seen at
day 8.
Effect of HEBP on Gene Expression (Fig. 5)
Expression of genes associated with cementoblast
maturation is a useful tool to assess changes in phe-
notype. Key markers for mineral associated proteins
in bone, which are valid for cementum, include Cbfa1,
BSP, OCN, and OPN. No noticeable modification in
expression of the genes of interest was noted in cells
treated with HEPB for 1, 3, and 6 days regardless of
the HEBP concentration (data not shown). However,
at day 10, distinct changes in OCCM gene expression
were noted in cells exposed to HEBP versus untreated
control cells (Fig. 5). The master-switch gene for os-
teoblasts, Cbfa1, was downregulated at low doses
(0.01 and 0.1 mM) of HEBP, while no noticeable
alterations were seen at high doses (1.0 and 10.0
mM), compared to 2% FBS controls. Interestingly, this
Figure 2.
Effect of HEBP on cell viability. Trypan blue exclusion assay was
performed in parallel to proliferation assay. The assay, done three times,
showed no difference in OCCM viability following HEBP treatment
versus untreated controls (A, day 1; B, day 6; and C, day 10).
Figure 3.
Effect of HEBP on cell morphology. Cell morphology was observed
under a light microscope after exposure to HEBP (0.01, 0.1, 1.0,
and 10.0 mM) up to 10 days.
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contrast was found to be even more pronounced in
OCNmRNA levels relative to 2% FBS controls, a gene
known to be very responsive to Cbfa1. Conversely,
OPN mRNA levels were upregulated at low doses of
HEBP, whereas at high doses OPN, mRNA levels re-
mained comparable to the 2%FBScontrols. BSP gene
expression remained fairly constant and similar to un-
treated cells, regardless of the HEBP concentration
used.
DISCUSSION
Cementum, for the most part, is relatively inert, and
resorption in this part of the periodontium is not part
of physiologic metabolism but is usually related to in-
flammation or trauma. Following an insult to the ce-
mentum, cementoblasts and/or cells within the local
environment have the capacity to repair lost tissues.33
This study was designed to investigate the effect of
HEBP on the behavior of cementoblasts in vitro to de-
termine whether or not BPs have potential for use in
promoting periodontal regeneration.
Pyrophosphate as well as BP inhibit hydroxyapatite
crystal growth successfully and have anticalculus
properties.34-36 However, pyrophosphate in tooth-
paste is not delivered in a dose high enough to alter
cellular metabolism in the periodontium.
Both agents differ structurally and consequently in
their hydrolytic stability with respect to the actions of
pyrophosphatase and alkaline phosphatase: BPs are
resistant to both enzymes, while PPi is hydrolyzed
by these enzymes. Therefore, retention on hydroxy-
apatite surfaces is very long for BPs, but very short
for PPi. In relation to this, BPs interfere with minerali-
zation in a definitive manner since they are hydrolyt-
ically stable, while pyrophosphate is hydrolytically
unstable and is degraded in the oral cavity.34 How-
ever, of paramount importance is the concentration-
dependent critical level to inhibit mineralization of
each agent. As shown in our study, HEBP concentra-
tions of 10 and 1mM inhibitedmineralization, whereas
concentrations of 0.1 and0.01mMwere not inhibitory.
Damage to mature tooth mineral has not been re-
ported for pyrophosphates, and for HEBP, minor cal-
cium was released from enamel using an in vitro
system, but at a HEBP concentration 106 times higher
than in our experiments.36
Figure 4.
Effect of HEBP on mineralization. von Kossa staining served to visualize mineralization, whereas alizarin red S was used for quantification.
In previous studies, OCCMs were shown to be capable of promoting mineral formation within 8 days in vitro. OCCMs were cultured in mineralization
media and HEBP (0.01 to 10.0 mM).
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Bisphosphonates are clinically relevant as anti-
osteoporosis and anticancer medications. The BP
used here, HEBP,††† is a first generation BP used ini-
tially for the treatment of Paget’s disease and hyper-
calcemia of malignancy and belongs to the class of
N-BPs. For treatment of osteoporosis, the non-N-BP
alendronate is classically used, whereas for the treat-
ment of bone metastases, the latest generations of
N-BPs (pamidronate, zoledronic acid, and ibadronate)
are now used. These newly developed N-BPs are up to
20,000 times more potent than HEBP with respect to
their ability to inhibit osteoclast function anddiffer from
HEBP in their mechanistic action leading to apoptosis.
However, they have about the same ability to inhibit
mineralization as HEBP on a mole for mole basis, but
inasmuch as they are administered in a much lower
dose than HEBP for inhibition of osteoclast activity,
their effects on mineralization are minimal.
The results shown here indicate that HEBP did not
alter cementoblast proliferation, viability, and mor-
phological characteristics. This is in contrast to re-
ports indicating an increase in osteoblast and
preosteoblast proliferation5,7 and cell viability37 at
comparable HEBP concentrations. The ability to
promotemineral formation in cementoblasts revealed
two clear responses to HEBP exposure: either miner-
Figure 5.
A) The expression of mineral-associated genes were examined: Cbfa1, OCN, Col I, BSP, and OPN. OCCMs were cultured in mineralization media
and HEBP (0.01 to 10.0 mM). The total RNA was extracted from cells after 10 days of treatment and the expression of transcripts was determined
by Northern blot analysis. The blots are representative results from one experiment, with similar results in all three experiments. The housekeeping
gene 18S ribosomal RNA serves as an endogenous control. B) Results were normalized with 18S rRNA and are displayed with bar graphs.
After normalization to 18S, distinct differences were noted between BP-treated OCCM-30 and untreated OCCM-30, and these varied depending
on the dose delivered.
††† Didronel, Procter & Gamble Pharmaceuticals, Cincinnati, OH.
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alization was abolished at high doses (1.0 mM and
10.0 mM) or mineralization equal to the control oc-
curred at lower doses (0.01mM and 0.1 mM). As ce-
mentoblasts and osteoblasts are thought to have
a similar origin, it is interesting to note that cemento-
blast behavior in our study diverged in some aspects
from osteoblast behavior in the literature. The un-
changed level of mineralization in cementoblasts at
lower doses was not expected, because a number of
previous studies showed that HEBP at comparable
doses increases mineral formation in cultured osteo-
blasts.5,7,21The lack ofmineralization associatedwith
BPsmanifests clinically as osteomalacia. The high af-
finity of BPs to apatite results in physicochemical
blocking of mineralization at a high concentration of
BPs in vitro and in clinic.38,39 Analysis of crystals by
electron microscope (EM) is one way of evaluating
biomineralization, and in previous studies with cemen-
toblasts, using EM analysis in vitro and a severe
combined immunodeficiency (SCID) mouse model
in vivo, we have shown that the positive stain, in vitro,
correlatedwith biomineralization.23Biomineralization
involves many aspects, including the formation and
orientation of crystalline materials and the composi-
tion of extracellular matrix proteins. Therefore, the
analysis of genes associated with mineral formation
mayprovide further clues for the initiation and promo-
tion of biomineralization. However, in our study, none
of the changes in gene expression were clearly related
to changes in mineralizing ac-
tivity. Only low doses of HEBP
induced changes at the mRNA
level in a dose-dependent fash-
ion. The parallel downregula-
tion of Cbfa1 mRNA and OCN
mRNA is remarkable, since
Cbfa1, as a transcription factor
for osteoblast/cementoblast
differentiation, is closely con-
nected to the regulation of
OCN expression.40
It is significant to our findings
that Cbfa1 exhibits opposite
functions in immature and ma-
ture osteoblasts.41 In immature
cells, it positively regulates
osteoblast differentiation, but
at late stages of cell develop-
ment, it does not seem to be
important. In our study, the
mineralmatrixmight havebeen
already developed by mature
cementoblasts. Mineralization
occurs and is not pronounced
as reported in OCN deficient
mice42 with decreased crystal
size/perfection.43 It is speculative that physicochem-
ical events are superimposed, since mineral forma-
tion depends on many factors, and that a delicate
balance of several genes/ECM proteins is crucial for
mineralization of root cementum.
Interestingly, both cementoblasts44 and osteo-
blasts respond to inorganic phosphate with an in-
crease in OPN at the mRNA and protein level.45,46
Phosphate enters the cell through a Na-dependent
phosphate transporter. Whether or not HEBP could
serve as a phosphate source is still not clear, but it
would help to explain the OPN mRNA upregulation
in our experiments. Phosphate seems to play a prom-
inent role in cementum metabolism. Individuals with
the genetic predisposition to low levels of tissue
non-specific ALP (TNSALP) exhibit severely reduced
or the lack of cementum formation and subsequently
the loss of teeth at an early age.47 Conversely, more
recent data shows that mice having mutations in
genes that regulate pyrophosphate in the local envi-
ronment (e.g., the multipass transmembrane protein
or ankylosis protein [ANK] and plasma cell mem-
brane glycoprotein-1[PC-1]), resulting in decreased
levels of extracellular PPi, exhibit a phenotype with in-
creased cementum formation.44 Osteoblasts and ce-
mentoblasts44 of thesemice in vitro and osteoblasts in
vivo were characterized by reduced OPN mRNA and
protein levels. Further, OPN ablation increased the
mineral content andmineral crystallinity in transgenic
Figure 6.
Hypothetical model for the action of HEBP on the bone and cementum of the periodontium. HEBP
may activate bone remodeling by stimulating osteoclast activation, followed by formation and
ultimately leading to the reduction of the osseous defect and narrowing of the periodontal ligament. In
contrast, cementum has limited remodeling activity and thus may be relatively inert to HEBP; i.e.,
cementoblasts may play a critical role in protecting the root surface from osteoclast-mediated bone
resorption.
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mice.48Thus, it is evident that exposure of osteoblasts
and cementoblasts to phosphate and pyrophosphate
alters expression of OPN, but the significance of this
effect is still not clear. As an early bone marker,
ALP is present on the osteoblast cell surface and in-
side of matrix vesicles released by mineral-forming
cells. Existing data indicates that HEBP inhibits ALP
by complexing with Zn2+ in the active center of the en-
zyme,49 thereby inhibiting the breakdown of organic
phosphates and mineralization.50 Increased ALP ac-
tivity was noted in an osteogenesis model following
HEBP treatment,5 but in our study with cemento-
blasts, this was not confirmed (data not shown). In
agreement with others, ALP levels appeared to be
very low in cementoblasts.51 In general, differences in
results can be attributed to several factors including
dissimilarities in cell type, stage of maturation, dura-
tion, and dose of treatment, origin of cells, and assay
used. In any event, these findings, while very specula-
tive at this point, support the notion that cemento-
blasts are quite different from osteoblasts in some
respects. It appears that under in vitro conditions
the cells used for our studies may be less sensitive
than osteoblasts to the physicochemical properties
of HEBP at low concentration.
Following an insult to the cementum, cemento-
blasts and/or cells within the local environment have
the capacity to repair lost tissues.33 Indeed, it might
be that cementum, despite its similarities to bone, is
different enough as to protect root surfaces from re-
modeling, thus controlling ankylosis and resorption
(Fig. 6). This would be consistent with the notable
differences between HEBP-mediated effects on ce-
mentoblasts as compared to osteoblasts. Our in vitro
data revealed that cementoblasts respond quite dis-
tinctly to HEBP treatment. In comparison to animal
studies following HEBP, the doses typically used in
mice, ‡8 mg phosphorus/kg body weight/day, are
higher in concentration compared to in vitro studies.
This high concentration was intentionally chosen to
inhibit cementum mineralization and to study the
periodontal attachment.52 However, at lower doses
of HEBP (£6 mg phosphorus/kg body weight/day),
acellular cementum was formed.52 Cell-containing
tissues in mice, bone,53 and cellular cementum54
seemed to respond distinctly to daily subcutaneous
HEBP injections of 15 mg/kg body weight53 or 10
mg/kg body weight.54 The PDL width appeared to
narrow as a consequence of the formation of alveolar
bone,53 at times to the point of ankylosis.54 Further,
the cellular cementum at the apex was bulged out.54
Nevertheless, these reported studies did not deter-
mine the thickness of cementum histomorphometri-
cally.
In bone remodeling, anabolic and catabolic actions
are coupled. In cementum, resorption does not occur
under physiological circumstances, and only after
marked trauma to cementoblasts. It has been sug-
gested that cementum/cementoblasts have a less
responsive metabolism when compared to bone/
osteoblasts. The details of interaction are unknown,
but osteoclastic activity seems to relate to the status
of cementoblasts in terms of injury versus recov-
ery.55,56 Interestingly, the antiresorptive property of
HEBP proved beneficial as it limited the amount of
root resorption in a mouse model.57 Moreover, ce-
mentoblasts are claimed to posses an invasion pro-
tective function against osteoclast/cementoclast.
Once cementoblasts are removed, resorptive cells
are unable to differentiate between cementum and
bone and induce root and bone resorptions. In our
study, cementoblasts demonstrated low responsive-
ness to a potent stimulus (HEBP) for osteoblasts
(Table 1; Fig. 5). Neither anabolic nor catabolic events
were induced directly, as measured by proliferation,
gene and protein expression supportive for ECM for-
mation, and mineralization. Overall, the differences
in the response of osteoblasts versus cementoblasts
to HEBP support the concept that cementoblasts con-
tribute to periodontal homeostasis. Caution must be
takenwith this interpretationbecause thepresent study
lacks a direct comparison of cementoblast and osteo-
blast cell lines from the same animal and does not
include validating in vivo studies. Future studies
including examining other genes and earlier time
points along with parallel animal studies would be of
value to clarify direct/indirect effects and to determine
the value of using bisphosphonates in the treatment of
diseases of the periodontium.
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